Bedel Financial Consulting, Inc. Bristol Myers Squibb CO Transaction History

Bedel Financial Consulting, Inc.

$690 Million
Q4 2024

A detailed history of Bedel Financial Consulting, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bedel Financial Consulting, Inc. holds 5,690 shares of BMY stock, worth $340,831. This represents 0.05% of its overall portfolio holdings.

Number of Shares

5,690

Previous 5,515 3.17%

Holding current value

$340,831

Previous $285,000 12.63%

% of portfolio

0.05%

Previous 0.04%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	BUY	$51.92 - $59.94 $9,086 - $10,489	175 Added 3.17%	5,690 $321,000
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $18,322 - $23,908	462 Added 9.14%	5,515 $285,000
Q2 2024 Aug 05, 2024	SELL	$40.25 - $52.99 $33,327 - $43,875	-828 Reduced 14.08%	5,053 $209,000
Q1 2024 May 07, 2024	BUY	$47.98 - $54.4 $479 - $544	10 Added 0.17%	5,881 $318,000
Q4 2023 Feb 08, 2024	BUY	$48.48 - $57.85 $436 - $520	9 Added 0.15%	5,871 $301,000
Q3 2023 Feb 08, 2024	BUY	$57.89 - $64.73 $405 - $453	7 Added 0.12%	5,862 $340,000
Q2 2023 Aug 10, 2023	BUY	$63.71 - $70.74 $101,617 - $112,830	1,595 Added 37.44%	5,855 $374,000
Q1 2023 May 02, 2023	SELL	$65.71 - $74.53 $104,741 - $118,800	-1,594 Reduced 27.23%	4,260 $295,000
Q3 2022 Nov 08, 2022	SELL	$0.13 - $76.84 $31 - $18,441	-240 Reduced 3.94%	5,854 $464,000
Q2 2022 Aug 04, 2022	SELL	$72.62 - $79.98 $12,926 - $14,236	-178 Reduced 2.84%	6,094 $469,000
Q1 2022 Apr 19, 2022	SELL	$61.48 - $73.72 $2,828 - $3,391	-46 Reduced 0.73%	6,272 $458,000
Q4 2021 Jan 11, 2022	SELL	$53.63 - $62.52 $15,177 - $17,693	-283 Reduced 4.29%	6,318 $394,000
Q3 2021 Oct 12, 2021	BUY	$59.17 - $69.31 $295 - $346	5 Added 0.08%	6,601 $391,000
Q2 2021 Aug 03, 2021	BUY	$61.91 - $67.42 $31,326 - $34,114	506 Added 8.31%	6,596 $441,000
Q1 2021 Apr 26, 2021	BUY	$59.34 - $66.74 $59,696 - $67,140	1,006 Added 19.79%	6,090 $384,000
Q4 2020 Feb 02, 2021	SELL	$57.74 - $65.43 $3,117 - $3,533	-54 Reduced 1.05%	5,084 $315,000
Q3 2020 Oct 20, 2020	BUY	$57.43 - $63.64 $287 - $318	5 Added 0.1%	5,138 $310,000
Q1 2020 May 06, 2020	SELL	$46.4 - $67.43 $18,096 - $26,297	-390 Reduced 7.06%	5,133 $286,000
Q4 2019 Jan 28, 2020	BUY	$49.21 - $64.19 $9,153 - $11,939	186 Added 3.49%	5,523 $354,000
Q3 2019 Oct 09, 2019	SELL	$42.77 - $50.71 $38,236 - $45,334	-894 Reduced 14.35%	5,337 $271,000
Q2 2019 Aug 01, 2019	BUY	$44.62 - $49.34 $223 - $246	5 Added 0.08%	6,231 $283,000
Q1 2019 May 02, 2019	BUY	$45.12 - $53.8 $45,345 - $54,069	1,005 Added 19.25%	6,226 $297,000
Q4 2018 Jan 28, 2019	SELL	$48.76 - $63.23 $223,710 - $290,099	-4,588 Reduced 46.77%	5,221 $271,000
Q3 2018 Nov 01, 2018	BUY	$55.19 - $62.25 $21,468 - $24,215	389 Added 4.13%	9,809 $567,000
Q2 2018 Jul 18, 2018	BUY	$50.53 - $62.98 $202 - $251	4 Added 0.04%	9,420 $521,000
Q1 2018 May 03, 2018	BUY	$59.92 - $68.98 $239 - $275	4 Added 0.04%	9,416 $596,000
Q4 2017 Feb 06, 2018	BUY	$59.94 - $65.35 $564,155 - $615,074	9,412	9,412 $577,000

Others Institutions Holding BMY

# of Institutions

2,763

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $127B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bedel Financial Consulting, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bedel Financial Consulting, Inc. with notifications on news.

Account

Bedel Financial Consulting, Inc. Bristol Myers Squibb CO Transaction History